These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32382359)

  • 41. Prevalence of Human Immunodeficiency Virus and associated factors among Visceral Leishmaniasis infected patients in Northwest Ethiopia: a facility based cross-sectional study.
    Alemayehu M; Wubshet M; Mesfin N; Gebayehu A
    BMC Infect Dis; 2017 Feb; 17(1):152. PubMed ID: 28212625
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impaired Thymic Output Can Be Related to the Low Immune Reconstitution and T Cell Repertoire Disturbances in Relapsing Visceral Leishmaniasis Associated HIV/AIDS Patients.
    Silva-Freitas ML; Corrêa-Castro G; Cota GF; Giacoia-Gripp C; Rabello A; Teixeira Dutra J; de Vasconcelos ZFM; Savino W; Da-Cruz AM; Santos-Oliveira JR
    Front Immunol; 2020; 11():953. PubMed ID: 32508833
    [No Abstract]   [Full Text] [Related]  

  • 43. Visceral Leishmaniasis and HIV Co-Infection in Northwest Ethiopia: Antiretroviral Treatment and Burden of Disease among Patients Enrolled in HIV Care.
    van Griensven J; Simegn T; Endris M; Diro E
    Am J Trop Med Hyg; 2018 Feb; 98(2):486-491. PubMed ID: 29210347
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Visceral leishmaniasis in patients with HIV infection].
    Ribera E; Cucurull E; Ocaña I; Vallespí T; Gasser I; Juste C
    Enferm Infecc Microbiol Clin; 1995 Feb; 13(2):73-9. PubMed ID: 7711130
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum chemokine profiles in visceral leishmaniasis, HIV and HIV/ visceral leishmaniasis co-infected Ethiopian patients.
    Sisay Z; Berhe N; Petros B; Tegbaru B; Messele T; Hailu A; Wolday D
    Ethiop Med J; 2011 Jul; 49(3):179-86. PubMed ID: 21991751
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV.
    Adriaensen W; Cuypers B; Cordero CF; Mengasha B; Blesson S; Cnops L; Kaye PM; Alves F; Diro E; van Griensven J
    EBioMedicine; 2020 May; 55():102748. PubMed ID: 32361248
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
    Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
    PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Visceral leishmaniasis as an independent cause of high immune activation, T-cell senescence, and lack of immune recovery in virologically suppressed HIV-1-coinfected patients.
    Casado JL; Abad-Fernández M; Moreno S; Pérez-Elías MJ; Moreno A; Bernardino JI; Vallejo A
    HIV Med; 2015 Apr; 16(4):240-8. PubMed ID: 25604328
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Visceral leishmaniasis and HIV coinfection in Latin America.
    Lindoso JA; Cota GF; da Cruz AM; Goto H; Maia-Elkhoury AN; Romero GA; de Sousa-Gomes ML; Santos-Oliveira JR; Rabello A
    PLoS Negl Trop Dis; 2014 Sep; 8(9):e3136. PubMed ID: 25233461
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relapsing visceral leishmaniasis in a HIV-1 infected patient with advanced disease.
    Standaert D; Laurent F; Jonckheere S; Scheiff JM; Vandercam B; Yombi JC
    Acta Clin Belg; 2013; 68(2):124-7. PubMed ID: 23967722
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical aspects of visceral leishmaniasis caused by L. infantum in adults. Ten years of experience of the largest outbreak in Europe: what have we learned?
    Horrillo L; Castro A; Matía B; Molina L; García-Martínez J; Jaqueti J; García-Arata I; Carrillo E; Moreno J; Ruiz-Giardin JM; San Martín J
    Parasit Vectors; 2019 Jul; 12(1):359. PubMed ID: 31340851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disease severity in patients with visceral leishmaniasis is not altered by co-infection with intestinal parasites.
    Tajebe F; Getahun M; Adem E; Hailu A; Lemma M; Fikre H; Raynes J; Tamiru A; Mulugeta Z; Diro E; Toulza F; Shkedy Z; Ayele T; Modolell M; Munder M; Müller I; Takele Y; Kropf P
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005727. PubMed ID: 28732017
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region.
    Pasquau F; Ena J; Sanchez R; Cuadrado JM; Amador C; Flores J; Benito C; Redondo C; Lacruz J; Abril V; Onofre J;
    Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):411-8. PubMed ID: 15928908
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis.
    Marlais T; Bhattacharyya T; Singh OP; Mertens P; Gilleman Q; Thunissen C; Hinckel BCB; Pearson C; Gardner BL; Airs S; de la Roche M; Hayes K; Hafezi H; Falconar AK; Eisa O; Saad A; Khanal B; Bhattarai NR; Rijal S; Boelaert M; El-Safi S; Sundar S; Miles MA
    Front Cell Infect Microbiol; 2018; 8():427. PubMed ID: 30619774
    [No Abstract]   [Full Text] [Related]  

  • 55. Case study of a patient with HIV-AIDS and visceral leishmaniasis co-infection in multiple episodes.
    Silva ED; Andrade LD; Araújo PS; Silveira VM; Padilha CE; Silva MA; Medeiros ZM
    Rev Inst Med Trop Sao Paulo; 2013; 55(6):425-8. PubMed ID: 24213197
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Visceral leishmaniasis and HIV coinfection: current perspectives.
    Lindoso JAL; Moreira CHV; Cunha MA; Queiroz IT
    HIV AIDS (Auckl); 2018; 10():193-201. PubMed ID: 30410407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India.
    Mahajan R; Das P; Isaakidis P; Sunyoto T; Sagili KD; Lima MA; Mitra G; Kumar D; Pandey K; Van Geertruyden JP; Boelaert M; Burza S
    Clin Infect Dis; 2015 Oct; 61(8):1255-62. PubMed ID: 26129756
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
    Ritmeijer K; Veeken H; Melaku Y; Leal G; Amsalu R; Seaman J; Davidson RN
    Trans R Soc Trop Med Hyg; 2001; 95(6):668-72. PubMed ID: 11816442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Magnitude of visceral leishmaniasis and poor treatment outcome among HIV patients: meta-analysis and systematic review.
    Alemayehu M; Wubshet M; Mesfin N
    HIV AIDS (Auckl); 2016; 8():75-81. PubMed ID: 27042142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
    Ali A
    Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.